cd73in1

CD73-IN-1 is a CD73 inhibitor with anticancer activity.

CD73-IN-17 (compound 19) is an inhibitor of CD73 with an IC50 of 0.1 μM against hCD73. It is applicable in cancer research.

CD73-IN-16 (compound 18) acts as an inhibitor of hCD73, exhibiting an IC50 value of 0.28 μM.

CD73-IN-19 (Compound 4ab) is an inhibitor of CD73, demonstrating a 44% inhibition rate of CD73 enzyme activity at 100 μM. It entirely counters T cell proliferation blockade triggered by TCR activation (induced by CD73 activity) at 10 μM and 100 μM and inhibits hA2A receptor activity in HEK-293 cells with a Ki of 3.31 μM. CD73-IN-19 holds potential for research in the field of immune diseases.

PD-L1/CD-73-IN-1 (compound CC-5) is an inhibitor of PD-L1 and CD73, with IC50 values of 6 nM and 0.773 μM, respectively. It effectively inhibits tumor cell growth both in vitro and in vivo.

CD73-IN-15 (compound 12f) is a potent CD73 inhibitor with an IC50 of 60 nM, playing a significant role in cancer research.

CD73-IN-13 is able to be used in a medicament preparing for tumor-related diseases. CD73-IN-13 is a potent inhibitor of CD73 which is closely associated with tumor growth, angiogenesis and metastasis [1].

CD73-IN-10 can be used in preparing tumor-related diseases medicament. CD73-IN-10 is a potent CD73 inhibitor that can catalyze the adenosine production from extracellular 5'-phosphate adenosine (5'-AMP). Adenosine induces immunosuppression and can promote tumor proliferation and/or metastasis [1].

CD73-IN-11 is able to used for tumor-related diseases medicament preparing. CD73-IN-11 is an effective CD73 inhibitor. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP) which induce immunosuppression and promote tumor proliferation and/or metastasis [1].

CD73-IN-12 is a highly effective CD73 inhibitor that displays strong potential in tumor suppression. CD73, an enzyme intricately linked to tumor development, angiogenesis, and metastasis, is significantly inhibited by CD73-IN-12. This compound holds promise in the formulation of therapeutic medications targeting tumor-related diseases[1].